ScanScor WCFF Events
Total Events
6142
Fish Alarms
2546
Chart Now
3025
UP / DOWN / UNCERTAIN
866 / 1566 / 3710
Max Repricing
99%
Max Fade Risk
99%
| Created | Ticker | Direction | Alarm | Type | Risk | Headline | Reason |
|---|---|---|---|---|---|---|---|
|
2026-09-22 01:57:42
Story: 2026-09-21 21:56:16
|
PDSB
ID 6142
|
DOWN
Up 18% /
Down 72%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 67% Fade: 79% Thesis Break: 64%
Today:
0.68 -
0.92
|
PDSB SEC filing points to financing activity
Parse: PARSED
|
13D confirms large PIPE and warrant overhang already announced, reinforcing dilution pressure despite strategic investor optics.
Input: ADEQUATE -
Fresh filing is usable, but much of the financing was previously disclosed, reducing novelty.
|
|
2026-09-21 23:39:43
Story: 2026-09-21 19:37:00
|
AVXL
ID 6141
|
DOWN
Up 8% /
Down 58%
|
Fish: NO
Chart: YES
MEDIUM
|
WATCH_CHART
OTHER
PRNewswire RSS
|
Reprice: 34% Fade: 82% Thesis Break: 28%
Today:
2.28 -
2.46
|
Rosen Law Firm Encourages Anavex Life Sciences Corp. Investors to Inquire About Securities Class Action Investigation - AVXL
Parse: PARSED
|
Law firm investigation is usually derivative, but it can add modest near-term pressure to an already weak, credibility-damaged biotech chart.
Input: ADEQUATE -
Freshness and context are sufficient; this is not a core business catalyst and likely has limited standalone repricing power.
|
|
2026-09-21 23:35:54
Story: 2026-09-21 19:34:00
|
TYGO
ID 6140
|
DOWN
Up 5% /
Down 28%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 22% Fade: 85% Thesis Break: 18%
Today:
0.95 -
1.04
|
Rosen Law Firm Encourages Tigo Energy, Inc. Investors to Inquire About Securities Class Action Investigation - TYGO
Parse: PARSED
|
Repeat class-action solicitation tied to already-known August guidance cut, usually weak incremental price catalyst.
Input: ADEQUATE -
Recent duplicate lawsuit headline and known underlying event provide enough context to judge low incremental impact.
|
|
2026-09-21 22:20:09
Story: 2026-09-21 18:05:24
|
BOLT
ID 6139
|
DOWN
Up 12% /
Down 58%
|
Fish: NO
Chart: YES
MEDIUM
|
WATCH_CHART
INSIDER
ScanScor Filing Bot
|
Reprice: 41% Fade: 82% Thesis Break: 28%
Today:
3.20 -
3.75
|
BOLT insider purchase filing detected
Parse: PARSED
|
Filing cluster is mostly routine tax-withholding sales and tiny ESPP buys, limiting bullish signal and slightly favoring weak downside interpretation.
Input: ADEQUATE -
Form 4 excerpts clearly show de minimis purchases versus larger automatic vesting-related sales, enough for event-reaction classification.
|
|
2026-09-21 22:11:05
Story: 2026-09-21 18:10:00
|
CAPR
ID 6138
|
DOWN
Up 5% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 92% Thesis Break: 88%
Today:
8.65 -
9.10
|
1 WEEK CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Parse: PARSED
|
Repeat class-action deadline notice adds little new information after the prior FDA/adcom-driven collapse.
Input: ADEQUATE -
Recent headline history clearly shows this is repetitive legal-solicitation news, not a fresh operational catalyst.
|
|
2026-09-21 21:42:44
Story: 2026-09-21 17:40:00
|
LLY
ID 6137
|
UNCERTAIN
Up 18% /
Down 10%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 14% Fade: 72% Thesis Break: 4%
Today:
1150.00 -
1178.00
|
Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
Parse: PARSED
|
Factory groundbreaking is long-cycle capacity news, not a near-term revenue, regulatory, or clinical catalyst for a mega-cap.
Input: ADEQUATE -
Headline and context are sufficient to classify this as routine operational news with low immediate repricing impact.
|
|
2026-09-21 21:33:40
Story: 2026-09-21 17:30:38
|
PASG
ID 6136
|
DOWN
Up 8% /
Down 68%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 54% Fade: 72% Thesis Break: 66%
Today:
4.35 -
4.95
|
PASG SEC filing points to financing activity
Parse: PARSED
|
S-4/A tied to merger and offering language reinforces dilution and shell-risk concerns for a tiny biotech with weak operating fundamentals.
Input: ADEQUATE -
Filing appears materially relevant, though much excerpted language is boilerplate and should be confirmed against the amended merger terms.
|
|
2026-09-21 21:25:09
Story: 2026-09-21 17:21:03
|
TYRA
ID 6135
|
DOWN
Up 12% /
Down 68%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
FINANCING
ScanScor Filing Bot
|
Reprice: 41% Fade: 72% Thesis Break: 28%
Today:
24.40 -
26.20
|
TYRA SEC filing points to financing activity
Parse: PARSED
|
13G appears tied to the already announced offering, so downside overhang exists but this filing alone may be mostly follow-through noise.
Input: ADEQUATE -
Recent offering context is sufficient, but the filing itself looks ownership-related rather than a clearly new financing event.
|
|
2026-09-21 21:20:08
Story: 2026-09-21 17:07:57
|
HELP
ID 6134
|
UP
Up 62% /
Down 24%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
INSIDER
ScanScor Filing Bot
|
Reprice: 58% Fade: 67% Thesis Break: 28%
Today:
13.10 -
14.25
|
HELP insider purchase filing detected
Parse: PARSED
|
CEO bought 100,000 shares near market highs, a constructive signal, but repeated recent insider filings reduce novelty and raise fade risk.
Input: ADEQUATE -
Form 4 details are sufficient, but recent similar insider and financing filings make the standalone signal less clean.
|
|
2026-09-21 21:17:46
Story: 2026-09-21 17:15:00
|
HELP
ID 6133
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 12% Fade: 82% Thesis Break: 4%
Today:
13.10 -
13.95
|
Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
Parse: PARSED
|
Conference participation and fireside chat are routine IR events without new clinical, regulatory, financing, or partnership catalyst.
Input: ADEQUATE -
Story is clear and recent, but it lacks any concrete catalyst likely to drive durable repricing.
|
|
2026-09-21 21:09:42
Story: 2026-09-21 17:08:06
|
ATR
ID 6132
|
UNCERTAIN
Up 18% /
Down 22%
|
Fish: NO
Chart: NO
MEDIUM
|
ROUTINE_NEWS
REGULATORY
ScanScor Filing Bot
|
Reprice: 24% Fade: 12% Thesis Break: 14%
Today:
121.80 -
125.50
|
ATR files 8-K with regulatory language
Parse: PARSED
|
Rule-matched FDA language appears likely boilerplate in an 8-K, with no confirmed concrete regulatory action disclosed yet.
Input: NEED_MORE_FILINGS -
Need the actual 8-K item details or exhibit summary to determine whether this is a real catalyst or filing noise.
|
|
2026-09-21 21:05:08
Story: 2026-09-21 16:52:51
|
HELP
ID 6131
|
UNCERTAIN
Up 28% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
CLINICAL_DATA
ScanScor Filing Bot
|
Reprice: 24% Fade: 78% Thesis Break: 12%
Today:
13.10 -
14.25
|
HELP files foreign issuer report with market-relevant terms
Parse: PARSED
|
Poster presentations and 12-month analyses are already public conference-style updates, not a new material clinical or regulatory catalyst.
Input: ADEQUATE -
Filing text and same-day press release align, showing this is largely a repackaged conference update with limited fresh catalyst value.
|
|
2026-09-21 21:04:55
Story: 2026-09-21 17:02:46
|
PODD
ID 6130
|
DOWN
Up 12% /
Down 58%
|
Fish: YES
Chart: YES
LOW
|
WATCH_CHART
FINANCING
ScanScor Filing Bot
|
Reprice: 41% Fade: 63% Thesis Break: 28%
Today:
136.00 -
143.00
|
PODD SEC filing points to financing activity
Parse: PARSED
|
Possible financing or credit amendment language suggests modest downside repricing risk, but filing evidence looks noisy and may be largely boilerplate.
Input: NEED_MORE_FILINGS -
Need the actual 8-K item details and exhibits to confirm whether this is a new dilutive event or routine debt-document amendment.
|
|
2026-09-21 21:02:44
Story: 2026-09-21 17:00:58
|
TCRT
ID 6129
|
DOWN
Up 12% /
Down 78%
|
Fish: YES
Chart: YES
HIGH
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 74% Fade: 71% Thesis Break: 83%
Today:
1.08 -
1.32
|
TCRT SEC filing points to financing activity
Parse: PARSED
|
Fresh tiny registered direct offering signals dilution and cash stress for an illiquid microcap, creating immediate downside repricing risk.
Input: ADEQUATE -
Filing excerpts and recent offering context are sufficient to classify this as actionable financing-driven dilution risk.
|
|
2026-09-21 21:02:37
Story: 2026-09-21 17:01:03
|
WEAV
ID 6128
|
UP
Up 58% /
Down 12%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
REGULATORY
ScanScor Filing Bot
|
Reprice: 46% Fade: 35% Thesis Break: 8%
Today:
7.28 -
7.40
|
WEAV files 8-K with regulatory language
Parse: PARSED
|
HSR early termination de-risks the pending take-private and can tighten merger spread, but most deal value was already known.
Input: ADEQUATE -
Filing text clearly shows a current merger-closing milestone despite noisy rule tags.
|
|
2026-09-21 21:02:31
Story: 2026-09-21 17:02:00
|
CODX
ID 6127
|
DOWN
Up 12% /
Down 74%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 71% Fade: 67% Thesis Break: 81%
Today:
0.90 -
1.08
|
CODX SEC filing points to financing activity
Parse: PARSED
|
Proxy seeks approval for warrant-linked share issuance exceeding 20%, signaling likely dilution pressure in a fragile microcap.
Input: ADEQUATE -
Filing excerpts clearly indicate current warrant exercise approval tied to Nasdaq rules and meaningful potential dilution.
|
|
2026-09-21 21:01:31
Story: 2026-09-21 16:59:00
|
FTK
ID 6126
|
DOWN
Up 5% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 85% Thesis Break: 20%
Today:
29.80 -
31.20
|
FTK Investors Have Opportunity to Lead Flotek Industries, Inc. Securities Fraud Lawsuit
Parse: PARSED
|
Repeat class-action solicitation is stale legal noise, not a new operational, regulatory, or financing catalyst.
Input: ADEQUATE -
Recent headline history clearly shows this lawsuit notice has already circulated multiple times.
|
|
2026-09-21 20:58:12
Story: 2026-09-21 16:55:28
|
HSTM
ID 6125
|
UNCERTAIN
Up 20% /
Down 35%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
FINANCING
ScanScor Filing Bot
|
Reprice: 25% Fade: 80% Thesis Break: 20%
Today:
28.40 -
29.60
|
HSTM SEC filing points to financing activity
Parse: PARSED
|
13D appears to disclose an already announced private placement, so incremental repricing risk now looks limited despite mild dilution overhang.
Input: ADEQUATE -
Recent company news already disclosed the $40 million placement, reducing novelty and immediate event value of this filing.
|
|
2026-09-21 20:49:39
Story: 2026-09-21 16:47:14
|
VREX
ID 6124
|
DOWN
Up 10% /
Down 62%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
FINANCING
ScanScor Filing Bot
|
Reprice: 38% Fade: 28% Thesis Break: 55%
Today:
17.95 -
18.55
|
VREX SEC filing points to financing activity
Parse: PARSED
|
Proxy filing appears tied to deal/financing mechanics, creating modest downside headline risk but not a clear standalone fundamental catalyst.
Input: NEED_MORE_FILINGS -
Need the actual merger proxy details and transaction terms, since rule-matched excerpts may reflect boilerplate rather than new dilution.
|
|
2026-09-21 20:49:32
Story: 2026-09-21 16:47:49
|
JAGX
ID 6123
|
DOWN
Up 12% /
Down 74%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
COMPLIANCE
ScanScor Filing Bot
|
Reprice: 68% Fade: 88% Thesis Break: 81%
Today:
2.20 -
3.10
|
JAGX files 8-K with regulatory language
Parse: PARSED
|
8-K appears tied to reverse split and Nasdaq compliance, typically bearish for distressed microcaps despite possible brief volatility.
Input: ADEQUATE -
Need full 8-K text confirmation, but available evidence strongly suggests a compliance-driven reverse-split event.
|
|
2026-09-21 20:41:09
Story: 2026-09-21 16:39:00
|
IRON
ID 6122
|
DOWN
Up 3% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 8% Fade: 92% Thesis Break: 6%
Today:
67.50 -
69.20
|
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Parse: PARSED
|
Repeat plaintiff-law-firm investigation notice tied to an old CRL, with little new information and limited incremental repricing power.
Input: ADEQUATE -
Recent repeated identical headlines and the underlying February CRL make this low-novelty and low-urgency.
|
|
2026-09-21 20:41:05
Story: 2026-09-21 16:39:00
|
SPRY
ID 6121
|
DOWN
Up 3% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 8% Fade: 95% Thesis Break: 10%
Today:
4.20 -
4.45
|
SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
Parse: PARSED
|
Repeated class-action reminder is stale legal noise, not a new operational, clinical, or regulatory catalyst.
Input: ADEQUATE -
Recent headline history clearly shows this lawsuit notice has already circulated multiple times.
|
|
2026-09-21 20:39:00
Story: 2026-09-21 16:34:25
|
PTCT
ID 6120
|
UP
Up 68% /
Down 22%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
REGULATORY
ScanScor Filing Bot
|
Reprice: 61% Fade: 41% Thesis Break: 18%
Today:
64.20 -
68.50
|
PTCT files 8-K with clinical-trial language
Parse: PARSED
|
Completed ST-920 acquisition adds a BLA-stage gene therapy asset with near-term Q4 2026 submission catalyst, but much was previously announced.
Input: ADEQUATE -
Filing excerpts clearly show acquisition close and near-term BLA timing, enough for event-reaction assessment.
|
|
2026-09-21 20:35:08
Story: 2026-09-21 16:23:38
|
PRTA
ID 6119
|
UP
Up 58% /
Down 18%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
INSIDER
ScanScor Filing Bot
|
Reprice: 46% Fade: 62% Thesis Break: 28%
Today:
8.35 -
8.85
|
PRTA insider purchase filing detected
Parse: PARSED
|
Another sizable 10% owner open-market purchase is constructive, but repeated recent insider buys reduce novelty and raise pop-and-fade risk.
Input: ADEQUATE -
Filing shows a current 100,000-share purchase by a repeat 10% owner, enough for monitoring despite limited novelty.
|
|
2026-09-21 20:33:28
Story: 2026-09-21 16:31:00
|
AARD
ID 6118
|
DOWN
Up 3% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 8% Fade: 92% Thesis Break: 10%
Today:
5.40 -
5.65
|
AARD Deadline: AARD Investors with Losses in Excess of $100K Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit
Parse: PARSED
|
Another repetitive shareholder lawsuit reminder adds little new information and usually has minimal incremental price impact.
Input: ADEQUATE -
Recent headline history clearly shows this is repeated legal notice flow, not a fresh operating catalyst.
|
|
2026-09-21 20:32:47
Story: 2026-09-21 16:30:00
|
CVKD
ID 6117
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 88% Thesis Break: 12%
Today:
1.03 -
1.15
|
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
Parse: PARSED
|
Investor conference participation is routine and lacks a new clinical, regulatory, financing, or partnership catalyst.
Input: ADEQUATE -
News context and company profile are sufficient to classify this as non-actionable routine IR news.
|
|
2026-09-21 20:32:27
Story: 2026-09-21 16:30:15
|
NAMS
ID 6116
|
DOWN
Up 18% /
Down 72%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 66% Fade: 41% Thesis Break: 24%
Today:
21.60 -
23.10
|
NAMS SEC filing points to financing activity
Parse: PARSED
|
Fresh 8-K financing and warrant signals usually pressure biotech shares through dilution overhang, even if runway improves.
Input: NEED_MORE_FILINGS -
Need the actual 8-K terms, size, pricing, and counterparties to confirm dilution severity versus routine warrant housekeeping.
|
|
2026-09-21 20:32:18
Story: 2026-09-21 16:30:24
|
BCDA
ID 6115
|
UP
Up 58% /
Down 18%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
COMPLIANCE
ScanScor Filing Bot
|
Reprice: 46% Fade: 72% Thesis Break: 14%
Today:
1.04 -
1.22
|
BCDA files 8-K with regulatory language
Parse: PARSED
|
Regained Nasdaq minimum bid compliance removes a near-term overhang, but this microcap setup still carries high pop-and-fade risk.
Input: ADEQUATE -
Filing text clearly shows compliance restoration; no substantive FDA catalyst appears in the provided excerpts.
|
|
2026-09-21 20:32:07
Story: 2026-09-21 16:30:35
|
NTHI
ID 6114
|
DOWN
Up 28% /
Down 67%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 61% Fade: 74% Thesis Break: 31%
Today:
3.00 -
3.55
|
NTHI SEC filing points to financing activity
Parse: PARSED
|
8-K ties to recent financing and capital-structure changes, keeping dilution sensitivity elevated despite preferred redemption removing a worse overhang.
Input: ADEQUATE -
Filing excerpts and recent related news are sufficient to flag near-term repricing risk, though full 8-K parsing would refine severity.
|
|
2026-09-21 20:31:54
Story: 2026-09-21 16:30:41
|
SNGX
ID 6113
|
DOWN
Up 12% /
Down 78%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 74% Fade: 71% Thesis Break: 83%
Today:
0.33 -
0.40
|
SNGX SEC filing points to financing activity
Parse: PARSED
|
Microcap ATM expansion signals likely dilution and runway stress, creating immediate downside attention despite possible brief reflex volatility.
Input: ADEQUATE -
Filing evidence is sufficient to flag dilution risk, though some extracted tags appear boilerplate rather than core catalysts.
|
|
2026-09-21 20:31:22
Story: 2026-09-21 16:30:00
|
RNA
ID 6112
|
UNCERTAIN
Up 4% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
INSIDER
PRNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 6%
Today:
8.85 -
9.45
|
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Inducement grant PR is routine compensation disclosure, recently repeated, and lacks clinical, regulatory, financing, or partnership substance.
Input: ADEQUATE -
News context and trading setup are sufficient to classify this as non-actionable routine disclosure.
|
|
2026-09-21 20:31:17
Story: 2026-09-21 16:30:00
|
BDX
ID 6111
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 2%
Today:
179.00 -
182.50
|
Arthur Hu to Join BD as Chief Information and Digital Officer
Parse: PARSED
|
Executive CIO appointment is routine leadership news without clinical, regulatory, financial, or commercial catalyst likely to reprice BDX immediately.
Input: ADEQUATE -
Story and company context are sufficient to judge this as low-urgency routine corporate news.
|
|
2026-09-21 20:31:10
Story: 2026-09-21 16:30:00
|
PTCT
ID 6110
|
UNCERTAIN
Up 42% /
Down 28%
|
Fish: NO
Chart: YES
MEDIUM
|
WATCH_CHART
LICENSING
PRNewswire RSS
|
Reprice: 46% Fade: 58% Thesis Break: 18%
Today:
63.90 -
67.80
|
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
Parse: PARSED
|
Deal close was previously announced, but BLA-stage asset transfer and Q4 BLA timing can still cause moderate repricing attention.
Input: ADEQUATE -
Need exact acquisition economics and whether closing conditions changed versus the August announcement.
|
|
2026-09-21 20:30:13
Story: 2026-09-21 16:16:04
|
HYFT
ID 6109
|
UNCERTAIN
Up 8% /
Down 10%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
COMPLIANCE
ScanScor Filing Bot
|
Reprice: 14% Fade: 78% Thesis Break: 6%
Today:
1.41 -
1.52
|
HYFT files foreign issuer report with market-relevant terms
Parse: PARSED
|
6-K appears to be routine AGM notice language, not a concrete FDA, Nasdaq, or financing catalyst.
Input: ADEQUATE -
Filing excerpts indicate meeting logistics only; rule tags likely overcalled materiality.
|
|
2026-09-21 20:27:17
Story: 2026-09-21 16:23:41
|
ANAB
ID 6108
|
UNCERTAIN
Up 10% /
Down 38%
|
Fish: NO
Chart: NO
MEDIUM
|
ROUTINE_NEWS
FINANCING
ScanScor Filing Bot
|
Reprice: 24% Fade: 72% Thesis Break: 18%
Today:
53.00 -
56.50
|
ANAB SEC filing points to financing activity
Parse: PARSED
|
Detected financing language appears historical within a 10-KT, not a clearly new offering or immediate dilution event.
Input: ADEQUATE -
Need actual offering terms or a dedicated financing filing before treating this as actionable repricing news.
|
|
2026-09-21 20:24:21
Story: 2026-09-21 16:21:01
|
ABVX
ID 6107
|
UNCERTAIN
Up 15% /
Down 35%
|
Fish: NO
Chart: YES
MEDIUM
|
WATCH_CHART
FINANCING
ScanScor Filing Bot
|
Reprice: 30% Fade: 70% Thesis Break: 20%
Today:
100.00 -
106.00
|
ABVX SEC filing points to financing activity
Parse: PARSED
|
F-6EF suggests ADS/ATM registration mechanics, but likely administrative after July financing rather than a clearly new dilutive capital raise.
Input: NEED_MORE_FILINGS -
Need linked prospectus supplement or ATM sales details to confirm whether this filing creates fresh near-term dilution pressure.
|
|
2026-09-21 20:21:50
Story: 2026-09-21 16:16:24
|
PACS
ID 6106
|
UNCERTAIN
Up 10% /
Down 28%
|
Fish: NO
Chart: NO
MEDIUM
|
IGNORE
FINANCING
ScanScor Filing Bot
|
Reprice: 22% Fade: 65% Thesis Break: 18%
Today:
40.90 -
42.80
|
PACS SEC filing points to financing activity
Parse: PARSED
|
Rule-based filing signal appears misclassified; excerpts indicate executive separation boilerplate, not a clear material financing catalyst.
Input: NEED_MORE_FILINGS -
Need the actual 8-K item summary or exhibits because provided evidence looks noisy and non-material.
|
|
2026-09-21 20:21:43
Story: 2026-09-21 16:17:00
|
USPH
ID 6105
|
UNCERTAIN
Up 12% /
Down 18%
|
Fish: NO
Chart: NO
MEDIUM
|
IGNORE
REGULATORY
ScanScor Filing Bot
|
Reprice: 22% Fade: 65% Thesis Break: 14%
Today:
80.50 -
84.50
|
USPH files 8-K with regulatory language
Parse: PARSED
|
Rule-matched FDA language in an 8-K appears likely boilerplate, with no clear concrete catalyst or material operational impact disclosed.
Input: NEED_MORE_FILINGS -
Need the actual 8-K item and exhibit details because the provided excerpt is noisy XBRL text, not confirmed catalyst content.
|
|
2026-09-21 20:21:28
Story: 2026-09-21 16:20:00
|
ANAB
ID 6104
|
UNCERTAIN
Up 18% /
Down 22%
|
Fish: NO
Chart: NO
MEDIUM
|
ROUTINE_NEWS
EARNINGS
ScanScor Filing Bot
|
Reprice: 24% Fade: 72% Thesis Break: 20%
Today:
53.50 -
56.80
|
ANAB files 8-K with clinical-trial language
Parse: PARSED
|
8-K appears tied to routine financial results and recycled partner-trial disclosures, not a clearly new ANAB-specific catalyst.
Input: ADEQUATE -
Need the actual 8-K item details, but current evidence suggests scanner tag noise rather than a fresh material catalyst.
|
|
2026-09-21 20:16:58
Story: 2026-09-21 16:15:00
|
ANAB
ID 6103
|
UNCERTAIN
Up 18% /
Down 22%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
EARNINGS
GlobeNewswire RSS
|
Reprice: 24% Fade: 72% Thesis Break: 14%
Today:
53.40 -
56.80
|
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
Parse: PARSED
|
Headline signals routine financial results and business update, with no disclosed clinical, regulatory, licensing, or financing catalyst.
Input: ADEQUATE -
Need full release details to reassess only if guidance, litigation, royalties, or capital allocation materially changed.
|
|
2026-09-21 20:14:40
Story: 2026-09-21 16:12:39
|
ABVX
ID 6102
|
DOWN
Up 18% /
Down 62%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
FINANCING
ScanScor Filing Bot
|
Reprice: 41% Fade: 58% Thesis Break: 22%
Today:
99.00 -
106.00
|
ABVX SEC filing points to financing activity
Parse: PARSED
|
Likely financing-related 6-K suggests dilution overhang, but evidence may partly reflect prior offering disclosures rather than a clearly new capital raise.
Input: NEED_MORE_FILINGS -
Need the actual 6-K details to confirm whether this is a fresh offering event or recycled historical financing language.
|
|
2026-09-21 20:14:09
Story: 2026-09-21 16:13:14
|
ZCMD
ID 6101
|
DOWN
Up 12% /
Down 74%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 68% Fade: 86% Thesis Break: 79%
Today:
0.70 -
0.86
|
ZCMD SEC filing points to financing activity
Parse: PARSED
|
Likely dilution-related 6-K on a fragile reverse-split microcap creates immediate downside attention, though any reaction may be noisy and fade-prone.
Input: NEED_MORE_FILINGS -
Rule-matched excerpts look partly boilerplate, so the exact financing terms need direct filing review.
|
|
2026-09-21 20:11:57
Story: 2026-09-21 16:10:24
|
GTBP
ID 6100
|
DOWN
Up 12% /
Down 78%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 74% Fade: 67% Thesis Break: 71%
Today:
6.10 -
7.60
|
GTBP SEC filing points to financing activity
Parse: PARSED
|
8-K signals private placement and warrants, a classic microcap dilution overhang likely to pressure shares despite possible runway extension.
Input: ADEQUATE -
Filing excerpts are sufficient to flag likely dilution, though full pricing terms would improve precision.
|
|
2026-09-21 20:11:47
Story: 2026-09-21 16:10:47
|
TVTX
ID 6099
|
DOWN
Up 15% /
Down 68%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 61% Fade: 42% Thesis Break: 28%
Today:
59.50 -
63.80
|
TVTX SEC filing points to financing activity
Parse: PARSED
|
Rule-detected 8-K financing/offering signals imply possible dilution, which can pressure a large-cap biotech even if runway improves.
Input: NEED_MORE_FILINGS -
Need the actual 8-K terms because excerpts look noisy and may include boilerplate rather than confirmed financing details.
|
|
2026-09-21 20:11:06
Story: 2026-09-21 16:07:00
|
CVRX
ID 6098
|
UNCERTAIN
Up 8% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 14% Fade: 78% Thesis Break: 10%
Today:
2.88 -
3.08
|
CVRx Appoints John Landry as Chief Financial Officer
Parse: PARSED
|
CFO appointment is routine management news without financing, guidance, strategic transaction, or operating catalyst.
Input: ADEQUATE -
Headline-only management change is sufficient here because no concrete catalyst or filing-linked financial implication is disclosed.
|
|
2026-09-21 20:07:19
Story: 2026-09-21 16:05:37
|
IMDX
ID 6097
|
UNCERTAIN
Up 22% /
Down 28%
|
Fish: NO
Chart: YES
LOW
|
WATCH_CHART
OTHER
ScanScor Filing Bot
|
Reprice: 31% Fade: 74% Thesis Break: 34%
Today:
3.72 -
4.35
|
IMDX files 8-K with regulatory language
Parse: PARSED
|
8-K appears tied to legacy merger amendment language, with unclear current FDA or compliance impact and limited evidence of a clean catalyst.
Input: NEED_MORE_FILINGS -
Need the actual 8-K items and exhibits reviewed directly because the scan tags likely include boilerplate and historical merger text.
|
|
2026-09-21 20:07:13
Story: 2026-09-21 16:05:47
|
LNTH
ID 6096
|
UNCERTAIN
Up 18% /
Down 22%
|
Fish: NO
Chart: NO
MEDIUM
|
ROUTINE_NEWS
OTHER
ScanScor Filing Bot
|
Reprice: 28% Fade: 72% Thesis Break: 24%
Today:
99.20 -
101.50
|
LNTH files 8-K with regulatory language
Parse: PARSED
|
8-K appears to mainly update routine merger antitrust timing, not a new approval, financing shock, or deal break.
Input: ADEQUATE -
Filing excerpts indicate mostly previously disclosed merger process language, limiting immediate catalyst clarity.
|
|
2026-09-21 20:07:07
Story: 2026-09-21 16:05:54
|
PDSB
ID 6095
|
UNCERTAIN
Up 34% /
Down 28%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
OTHER
ScanScor Filing Bot
|
Reprice: 41% Fade: 82% Thesis Break: 24%
Today:
0.76 -
0.95
|
PDSB files 8-K with clinical-trial language
Parse: PARSED
|
8-K appears largely promotional and repeats known pipeline/regulatory language, but this volatile microcap can still react sharply and fade.
Input: NEED_MORE_FILINGS -
Need the actual 8-K item and exhibits to confirm whether this is a new material event or recycled investor presentation language.
|
|
2026-09-21 20:07:06
Story: 2026-09-21 16:05:00
|
MLYS
ID 6094
|
UNCERTAIN
Up 3% /
Down 7%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
INSIDER
GlobeNewswire RSS
|
Reprice: 8% Fade: 85% Thesis Break: 2%
Today:
27.90 -
28.60
|
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement equity grant for one employee is immaterial and repeated, with negligible valuation impact.
Input: ADEQUATE -
News context clearly shows repeated inducement-award releases, supporting low catalyst significance.
|
|
2026-09-21 20:07:01
Story: 2026-09-21 16:05:00
|
ABVX
ID 6093
|
UNCERTAIN
Up 22% /
Down 28%
|
Fish: NO
Chart: NO
MEDIUM
|
ROUTINE_NEWS
EARNINGS
GlobeNewswire RSS
|
Reprice: 24% Fade: 18% Thesis Break: 20%
Today:
100.00 -
107.00
|
Abivax présente les dernières avancées de ses activités et ses résultats financiers du premier semestre 2026
Parse: PARSED
|
Headline signals routine business update and half-year financials, with no disclosed clinical, regulatory, partnership, or financing catalyst.
Input: ADEQUATE -
Need the full release details, but current headline alone suggests low-urgency routine earnings-style news.
|
|
2026-09-21 20:06:49
Story: 2026-09-21 16:05:00
|
ABVX
ID 6092
|
UNCERTAIN
Up 18% /
Down 22%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
EARNINGS
GlobeNewswire RSS
|
Reprice: 24% Fade: 72% Thesis Break: 14%
Today:
100.00 -
107.00
|
Abivax Presents Business Updates and First Half 2026 Financial Results
Parse: PARSED
|
Business update and half-year financials alone lack a fresh concrete catalyst versus recent FDA and financing news.
Input: ADEQUATE -
Headline-only earnings release with no disclosed surprise catalyst supports low urgency classification.
|
|
2026-09-21 20:04:44
Story: 2026-09-21 16:01:00
|
NYXH
ID 6091
|
UNCERTAIN
Up 8% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 16% Fade: 72% Thesis Break: 14%
Today:
1.42 -
1.54
|
Nyxoah Annonce une Transition au Poste de Chief Financial Officer
Parse: PARSED
|
CFO transition alone is usually non-catalytic and lacks financing, guidance, regulatory, or clinical implications.
Input: ADEQUATE -
Headline and context are sufficient to classify this as routine management-change news with limited immediate repricing relevance.
|
|
2026-09-21 20:04:31
Story: 2026-09-21 16:01:00
|
NYXH
ID 6090
|
DOWN
Up 8% /
Down 34%
|
Fish: NO
Chart: NO
MEDIUM
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 22% Fade: 18% Thesis Break: 20%
Today:
1.40 -
1.52
|
Nyxoah Announces Chief Financial Officer Transition
Parse: PARSED
|
CFO transition is usually non-catalytic routine management news unless tied to financing, controls, or strategic disruption, which is not indicated here.
Input: ADEQUATE -
Headline-only management transition limits nuance, but enough context exists to classify this as low-urgency routine news.
|
|
2026-09-21 20:04:19
Story: 2026-09-21 16:01:00
|
XENE
ID 6089
|
UNCERTAIN
Up 6% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 78%
Today:
38.20 -
39.80
|
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Parse: PARSED
|
Investor conference presentation notice is routine and lacks new clinical, regulatory, financing, or partnership substance.
Input: ADEQUATE -
Fresh headline is clear and recent context already explains the major repricing catalyst.
|
|
2026-09-21 20:02:46
Story: 2026-09-21 16:01:07
|
WW
ID 6088
|
UNCERTAIN
Up 18% /
Down 22%
|
Fish: NO
Chart: NO
MEDIUM
|
ROUTINE_NEWS
OTHER
ScanScor Filing Bot
|
Reprice: 24% Fade: 78% Thesis Break: 20%
Today:
15.70 -
17.20
|
WW files 8-K with regulatory language
Parse: PARSED
|
Rule-matched 8-K/A appears dominated by boilerplate and amendment language, with no clear fresh catalyst confirmed from the provided excerpts.
Input: NEED_MORE_FILINGS -
Need the actual amended 8-K item details; current FDA and Nasdaq tags look likely boilerplate or false-positive term matches.
|
|
2026-09-21 20:02:37
Story: 2026-09-21 16:01:07
|
SGMO
ID 6087
|
DOWN
Up 8% /
Down 86%
|
Fish: YES
Chart: YES
HIGH
|
STRAY_WILDCAT_DOWN
COMPLIANCE
ScanScor Filing Bot
|
Reprice: 78% Fade: 22% Thesis Break: 97%
Today:
-
|
SGMO files 8-K with regulatory language
Parse: PARSED
|
8-K confirms Chapter 11 asset sale completion and Nasdaq delisting effectiveness, reinforcing severe equity impairment risk.
Input: ADEQUATE -
Filing excerpts clearly show bankruptcy, completed asset disposition, and pending delisting, enough for immediate event-reaction assessment.
|
|
2026-09-21 19:55:11
Story: 2026-09-21 15:54:00
|
PRCT
ID 6086
|
UNCERTAIN
Up 3% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 8% Fade: 92% Thesis Break: 18%
Today:
18.20 -
18.80
|
PRCT Deadline: PRCT Investors with Losses in Excess of $100K Have Opportunity to Lead PROCEPT BioRobotics Corporation Securities Fraud Lawsuit
Parse: PARSED
|
Repeated class-action deadline reminder is stale legal solicitation, not a new operational, regulatory, or financing catalyst.
Input: ADEQUATE -
Recent headline history clearly shows this lawsuit notice is repetitive and unlikely to drive fresh repricing.
|
|
2026-09-21 19:30:21
Story: 2026-09-21 15:29:11
|
SPRU
ID 6085
|
UNCERTAIN
Up 18% /
Down 22%
|
Fish: NO
Chart: NO
MEDIUM
|
IGNORE
REGULATORY
ScanScor Filing Bot
|
Reprice: 24% Fade: 82% Thesis Break: 14%
Today:
1.98 -
2.22
|
SPRU files 8-K with regulatory language
Parse: PARSED
|
Rule-matched 8-K/A appears boilerplate and non-biotech; no clear material catalyst is visible from the filing summary.
Input: NEED_MORE_FILINGS -
Need the actual amended 8-K event details because the FDA tag likely reflects false-positive boilerplate text.
|
|
2026-09-21 19:24:33
Story: 2026-09-21 15:23:00
|
SPRY
ID 6084
|
UNCERTAIN
Up 5% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 92% Thesis Break: 10%
Today:
4.20 -
4.45
|
SPRY Stockholders with Large Losses Should Contact Robbins LLP About Leading the ARS Pharmaceuticals Inc. Class Action Before the October 5, 2026 Deadline
Parse: PARSED
|
Repeated shareholder lawsuit reminder adds little new information and usually does not create fresh biotech repricing.
Input: ADEQUATE -
Recent headline history clearly shows this is repetitive legal solicitation, not a new operating or regulatory catalyst.
|
|
2026-09-21 19:14:50
Story: 2026-09-21 15:13:00
|
ARDX
ID 6083
|
DOWN
Up 3% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 8% Fade: 92% Thesis Break: 18%
Today:
3.40 -
3.52
|
ARDX Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Ardelyx, Inc.
Parse: PARSED
|
Law-firm class action reminder is recycled post-drop litigation noise, not a fresh operational, regulatory, or financing catalyst.
Input: ADEQUATE -
Recent context clearly shows multiple similar lawsuit notices, making this low-novelty and unlikely to drive meaningful new repricing.
|
|
2026-09-21 18:26:33
Story: 2026-09-21 14:24:00
|
ENSG
ID 6082
|
DOWN
Up 3% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 10% Fade: 92% Thesis Break: 12%
Today:
171.50 -
175.50
|
Rosen Law Firm Encourages The Ensign Group, Inc. Investors to Inquire About Securities Class Action Investigation - ENSG
Parse: PARSED
|
Repeat plaintiff-lawyer investigation notice tied to old short-report allegations, with no new filing, facts, regulator action, or company update.
Input: ADEQUATE -
News context clearly shows this is repetitive legal-solicitation noise rather than a fresh catalyst.
|
|
2026-09-21 17:30:09
Story: 2026-09-21 13:15:59
|
RDY
ID 6081
|
UNCERTAIN
Up 18% /
Down 22%
|
Fish: NO
Chart: NO
MEDIUM
|
ROUTINE_NEWS
REGULATORY
ScanScor Filing Bot
|
Reprice: 24% Fade: 72% Thesis Break: 20%
Today:
12.20 -
12.60
|
RDY files foreign issuer report with market-relevant terms
Parse: PARSED
|
Rule-tagged 6-K lacks disclosed material details and resembles repeated foreign issuer filing noise, limiting immediate repricing odds.
Input: NEED_MORE_FILINGS -
Need the actual 6-K contents or exhibits to determine whether any FDA-related language reflects a current material event.
|
|
2026-09-21 17:12:24
Story: 2026-09-21 13:11:00
|
COO
ID 6080
|
DOWN
Up 8% /
Down 22%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 18% Fade: 85% Thesis Break: 12%
Today:
53.80 -
56.20
|
Rosen Law Firm Encourages The Cooper Companies, Inc. Investors to Inquire About Securities Class Action Investigation - COO
Parse: PARSED
|
Law-firm investigation notice is derivative of the prior earnings-driven drop and rarely creates fresh standalone repricing in a large-cap name.
Input: ADEQUATE -
Enough context shows this is repetitive legal-advertising noise after already digested bad guidance and strategic disappointment.
|
|
2026-09-21 16:28:24
Story: 2026-09-21 12:27:00
|
BBNX
ID 6079
|
UNCERTAIN
Up 8% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 92% Thesis Break: 28%
Today:
21.10 -
22.30
|
Beta Bionics (NASDAQ: BBNX) Faces Securities Class Action Amid iLet FDA Compliance -- HBSS
Parse: PARSED
|
Law-firm class action notice repeats known FDA compliance issues and usually adds little new price-moving information.
Input: ADEQUATE -
Recent headline history shows this lawsuit alert is repetitive, reducing immediate catalyst value.
|
|
2026-09-21 16:26:20
Story: 2026-09-21 12:25:00
|
HIMS
ID 6078
|
DOWN
Up 8% /
Down 22%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 88% Thesis Break: 68%
Today:
27.80 -
29.60
|
Hims & Hers Health (HIMS) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline
Parse: PARSED
|
Class-action filing is derivative of already-known FTC allegations and similar lawsuit alerts, so incremental repricing impact is likely limited.
Input: ADEQUATE -
Recent headline history clearly shows this is repetitive legal-advertising news rather than a fresh underlying catalyst.
|
|
2026-09-21 16:26:01
Story: 2026-09-21 12:23:00
|
VEEV
ID 6077
|
UNCERTAIN
Up 18% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 20% Fade: 72% Thesis Break: 8%
Today:
255.00 -
264.00
|
Veeva lance le Falcon Router pour le triage agentique de tous les canaux de reporting
Parse: PARSED
|
Product launch PR without disclosed revenue impact, customer win, or regulatory catalyst; likely incremental and already echoed in multiple language releases.
Input: ADEQUATE -
Story is clear and recent, but lacks financial magnitude or adoption details needed for stronger event-repricing conviction.
|
|
2026-09-21 16:22:17
Story: 2026-09-21 12:21:00
|
AARD
ID 6076
|
DOWN
Up 3% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 92% Thesis Break: 88%
Today:
5.10 -
5.45
|
AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (NASDAQ: AARD) to Filing of Securities Fraud Class Action
Parse: PARSED
|
Repeat class-action alert on already disclosed clinical-hold issues; incremental price impact is likely limited and low-quality.
Input: ADEQUATE -
Recent headline history clearly shows this lawsuit notice is repetitive rather than a fresh catalyst.
|
|
2026-09-21 16:14:20
Story: 2026-09-21 12:13:00
|
CAPR
ID 6075
|
DOWN
Up 3% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 8% Fade: 92% Thesis Break: 86%
Today:
8.75 -
9.20
|
CAPR 1-WEEK DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline
Parse: PARSED
|
Repeat class-action deadline alert adds little new information after prior FDA-driven collapse and multiple similar lawsuit notices.
Input: ADEQUATE -
Story is repetitive legal solicitation, not a fresh operational, regulatory, or financing catalyst.
|
|
2026-09-21 16:12:30
Story: 2026-09-21 12:10:00
|
PRCT
ID 6074
|
DOWN
Up 5% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 85% Thesis Break: 8%
Today:
18.20 -
19.10
|
PRCT FINAL DEADLINE ALERT: PROCEPT BioRobotics Corporation Investors Alerted to September 22, 2026 Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit
Parse: PARSED
|
Lead-plaintiff lawsuit reminder is repetitive, backward-looking, and usually non-catalytic after the core allegations were already absorbed.
Input: ADEQUATE -
Recent headline history clearly shows repeated lawsuit notices, reducing odds this specific alert drives fresh repricing.
|
|
2026-09-21 16:02:12
Story: 2026-09-21 12:00:00
|
CGEM
ID 6073
|
UNCERTAIN
Up 6% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 4%
Today:
20.60 -
21.40
|
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Parse: PARSED
|
Conference participation without new data, guidance, deal, or regulatory catalyst is routine and unlikely to drive meaningful repricing.
Input: ADEQUATE -
Story is clear and recent context confirms no new catalyst beyond an investor-facing forum appearance.
|
|
2026-09-21 15:25:09
Story: 2026-09-21 11:11:33
|
NVO
ID 6072
|
UNCERTAIN
Up 10% /
Down 20%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
ScanScor Filing Bot
|
Reprice: 18% Fade: 85% Thesis Break: 15%
Today:
38.90 -
40.80
|
NVO files foreign issuer report with market-relevant terms
Parse: PARSED
|
Detected 6-K appears to be routine buyback/listing disclosure, not a clear new material catalyst beyond already moving sentiment.
Input: ADEQUATE -
Need the full 6-K text to confirm no hidden regulatory update, but provided excerpt looks non-material.
|
|
2026-09-21 15:13:01
Story: 2026-09-21 11:12:00
|
ARDX
ID 6071
|
DOWN
Up 5% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 85% Thesis Break: 10%
Today:
3.34 -
3.48
|
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit
Parse: PARSED
|
Law-firm class action notice is derivative, already telegraphed, and rarely creates fresh standalone repricing in a liquid mid-cap biotech.
Input: ADEQUATE -
Recent similar lawsuit headlines and the underlying August commercial miss are already in context, making this notice low incremental value.
|
|
2026-09-21 14:35:43
Story: 2026-09-21 10:33:00
|
JNJ
ID 6070
|
UP
Up 58% /
Down 12%
|
Fish: NO
Chart: YES
MEDIUM
|
WATCH_CHART
REGULATORY
GlobeNewswire RSS
|
Reprice: 34% Fade: 42% Thesis Break: 8%
Today:
268.00 -
274.00
|
European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Parse: PARSED
|
EC approval is a real regulatory catalyst, but JNJ’s size makes immediate stock repricing likely modest rather than explosive.
Input: ADEQUATE -
Fresh approval headline and company scale are sufficient to judge this as watchlist-worthy but not a high-urgency fish alarm.
|
|
2026-09-21 14:02:54
Story: 2026-09-21 10:00:00
|
SNN
ID 6069
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 72% Thesis Break: 4%
Today:
27.30 -
27.85
|
Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
Parse: PARSED
|
Conference showcase language is routine marketing without new data, approvals, partnerships, or financial impact likely to reprice SNN immediately.
Input: ADEQUATE -
Headline and context are sufficient to classify this as non-actionable routine conference publicity.
|
|
2026-09-21 14:00:10
Story: 2026-09-21 09:48:51
|
HYFT
ID 6068
|
UNCERTAIN
Up 38% /
Down 22%
|
Fish: NO
Chart: YES
MEDIUM
|
WATCH_CHART
PARTNERSHIP
ScanScor Filing Bot
|
Reprice: 41% Fade: 78% Thesis Break: 18%
Today:
1.33 -
1.58
|
HYFT files foreign issuer report with market-relevant terms
Parse: PARSED
|
6-K appears to package a performance-validation deployment with AMD/Vultr, but lacks clear financing, FDA, or binding commercial catalyst.
Input: ADEQUATE -
Need full 6-K review to confirm whether this is merely promotional validation or includes material commercial terms.
|
|
2026-09-21 13:16:55
Story: 2026-09-21 09:15:00
|
QTTB
ID 6067
|
UP
Up 58% /
Down 18%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
CLINICAL_DATA
PRNewswire RSS
|
Reprice: 61% Fade: 72% Thesis Break: 28%
Today:
10.20 -
11.60
|
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
Parse: PARSED
|
Late-breaking trial presentation signals potentially supportive durability data, but this is still a conference-preview headline without the actual dataset.
Input: ADEQUATE -
Enough context exists to flag event-driven attention, though actual abstract details would improve conviction on magnitude and durability.
|
|
2026-09-21 13:16:19
Story: 2026-09-21 09:12:01
|
NSPR
ID 6066
|
DOWN
Up 22% /
Down 71%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 74% Fade: 68% Thesis Break: 41%
Today:
0.68 -
0.84
|
NSPR SEC filing points to financing activity
Parse: PARSED
|
Warrant amendments signal potential dilution and financing overhang, despite runway support tied to anticipated FDA approval.
Input: ADEQUATE -
Filing excerpts and matching press release provide enough detail to assess near-term dilution-driven reaction risk.
|
|
2026-09-21 13:16:13
Story: 2026-09-21 09:15:34
|
AVR
ID 6065
|
DOWN
Up 12% /
Down 68%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 61% Fade: 41% Thesis Break: 34%
Today:
7.75 -
8.35
|
AVR SEC filing points to financing activity
Parse: PARSED
|
424B3 prospectus supplement tied to registered selling stockholder shares signals likely dilution or overhang, creating near-term downside repricing risk.
Input: ADEQUATE -
Enough filing detail exists to classify this as financing-related overhang, though exact incremental dilution mechanics are not fully visible here.
|
|
2026-09-21 13:07:07
Story: 2026-09-21 09:05:27
|
RXRX
ID 6064
|
UP
Up 62% /
Down 24%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
LICENSING
ScanScor Filing Bot
|
Reprice: 68% Fade: 58% Thesis Break: 18%
Today:
3.72 -
4.25
|
RXRX files 8-K with regulatory language
Parse: PARSED
|
8-K appears to disclose a real Tempus licensing deal, which can reprice sentiment, but terms look incremental rather than thesis-changing.
Input: ADEQUATE -
Key filing excerpts show a current material agreement, while FDA and Nasdaq tags appear partly boilerplate and less decision-relevant.
|
|
2026-09-21 13:04:47
Story: 2026-09-21 09:00:00
|
PALI
ID 6063
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 4%
Today:
1.56 -
1.70
|
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Parse: PARSED
|
Conference presentation notice is routine, non-catalytic news with little standalone repricing power absent new data or financing details.
Input: ADEQUATE -
Headline and context are sufficient to classify this as routine investor-conference news without actionable catalyst content.
|
|
2026-09-21 13:02:40
Story: 2026-09-21 09:00:00
|
NAMS
ID 6062
|
UP
Up 82% /
Down 18%
|
Fish: YES
Chart: YES
HIGH
|
STRAY_WILDCAT_UP
REGULATORY
GlobeNewswire RSS
|
Reprice: 86% Fade: 38% Thesis Break: 9%
Today:
22.60 -
25.80
|
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Parse: PARSED
|
European Commission approval is a concrete commercialization catalyst, though some benefit was pre-signaled by prior positive CHMP opinion.
Input: ADEQUATE -
Key context is sufficient, including prior CHMP news, valuation, short interest, and recent price weakness.
|
|
2026-09-21 13:02:26
Story: 2026-09-21 09:00:00
|
AVLN
ID 6061
|
UP
Up 68% /
Down 22%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 61% Fade: 41% Thesis Break: 18%
Today:
30.60 -
34.80
|
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
Parse: PARSED
|
Fresh Phase 1 human data with lung-targeted exposure and tolerability can support near-term upside attention, though publication-style framing limits shock value.
Input: ADEQUATE -
Need exact efficacy and comparator details to judge whether this is materially new versus recent conference disclosures.
|
|
2026-09-21 13:02:13
Story: 2026-09-21 09:00:00
|
NSPR
ID 6060
|
DOWN
Up 22% /
Down 68%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
GlobeNewswire RSS
|
Reprice: 61% Fade: 74% Thesis Break: 58%
Today:
0.70 -
0.84
|
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
Parse: PARSED
|
Warrant amendments signal contingent dilution and cash need, with only indirect FDA timing support, creating likely pressure despite possible speculative approval-linked interest.
Input: ADEQUATE -
Headline and company context are sufficient to assess near-term financing-driven repricing risk.
|
|
2026-09-21 12:56:26
Story: 2026-09-21 08:55:40
|
TLX
ID 6059
|
DOWN
Up 22% /
Down 74%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 79% Fade: 41% Thesis Break: 36%
Today:
10.75 -
12.05
|
TLX SEC filing points to financing activity
Parse: PARSED
|
6-K appears tied to acquisition financing and possible share issuance, creating near-term dilution overhang despite strategic rationale.
Input: ADEQUATE -
Filing signal is noisy, but acquisition financing language and current price weakness make immediate downside monitoring warranted.
|
|
2026-09-21 12:47:31
Story: 2026-09-21 08:37:00
|
GOVX
ID 6058
|
UP
Up 58% /
Down 24%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_UP
PRECLINICAL
NewMediaWire RSS
|
Reprice: 63% Fade: 88% Thesis Break: 79%
Today:
0.34 -
0.52
|
GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models
Parse: PARSED
|
Preclinical single-dose mpox protection can spark a microcap bounce, but bioRxiv animal data and severe dilution history make fades likely.
Input: ADEQUATE -
News, market cap, price collapse, and recent financing/compliance context are sufficient for an event-reaction judgment.
|
|
2026-09-21 12:47:05
Story: 2026-09-21 08:45:00
|
ANIX
ID 6057
|
UNCERTAIN
Up 38% /
Down 18%
|
Fish: NO
Chart: YES
MEDIUM
|
WATCH_CHART
REGULATORY
PRNewswire RSS
|
Reprice: 34% Fade: 82% Thesis Break: 12%
Today:
2.74 -
3.15
|
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040
Parse: PARSED
|
Issued Australian patent modestly strengthens IP, but this is non-revenue, non-clinical, partly telegraphed news with likely pop-and-fade behavior.
Input: ADEQUATE -
Recent similar patent acceptance and Korean patent news reduce novelty, making immediate repricing potential limited despite small-cap sensitivity.
|
|
2026-09-21 12:37:30
Story: 2026-09-21 08:35:27
|
PETS
ID 6056
|
UNCERTAIN
Up 18% /
Down 22%
|
Fish: NO
Chart: NO
MEDIUM
|
ROUTINE_NEWS
OTHER
ScanScor Filing Bot
|
Reprice: 24% Fade: 72% Thesis Break: 28%
Today:
1.58 -
1.82
|
PETS files 8-K with regulatory language
Parse: PARSED
|
Detected tags appear driven by boilerplate and director appointment language, not a clear new regulatory, financing, or transaction catalyst.
Input: NEED_MORE_FILINGS -
Need the actual 8-K item details because the excerpts shown are noisy and likely misclassified by keyword matching.
|
|
2026-09-21 12:33:18
Story: 2026-09-21 08:30:00
|
PETS
ID 6055
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 12% Fade: 78% Thesis Break: 10%
Today:
1.62 -
1.76
|
PetMeds Enhances Board of Directors with Appointment of Tamar Elkeles as New Independent Director
Parse: PARSED
|
Independent director appointment is routine governance news without concrete financial, regulatory, or operating catalyst for immediate repricing.
Input: ADEQUATE -
News and company context are sufficient; no actionable catalyst is disclosed beyond board refresh.
|
|
2026-09-21 12:26:16
Story: 2026-09-21 08:24:00
|
VEEV
ID 6054
|
UNCERTAIN
Up 24% /
Down 14%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 18% Fade: 72% Thesis Break: 8%
Today:
255.00 -
264.00
|
Veeva stellt den „Falcon Router" für die agentenbasierte Triage aller Meldekanäle vor
Parse: PARSED
|
Product launch PR for an early-adopter AI workflow tool lacks revenue, customer, or regulatory catalyst and is unlikely to drive meaningful immediate repricing.
Input: ADEQUATE -
Story, company scale, and recent duplicate releases are sufficient to judge this as low-urgency routine product news.
|
|
2026-09-21 12:04:21
Story: 2026-09-21 08:00:00
|
NTHI
ID 6053
|
UNCERTAIN
Up 24% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 22% Fade: 86% Thesis Break: 20%
Today:
3.05 -
3.75
|
NeOnc Charting New Nasal Route to Treating Brain Cancer
Parse: PARSED
|
Promotional article language without new clinical, regulatory, financing, or partnership substance makes immediate repricing unlikely.
Input: ADEQUATE -
Headline and body lack concrete catalyst details, but recent context is sufficient to classify this as routine promotional news.
|
|
2026-09-21 12:04:08
Story: 2026-09-21 08:00:00
|
IMMP
ID 6052
|
DOWN
Up 8% /
Down 42%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
COMPLIANCE
GlobeNewswire RSS
|
Reprice: 38% Fade: 72% Thesis Break: 28%
Today:
0.26 -
0.31
|
Change to American Depositary Share Ratio
Parse: PARSED
|
ADS ratio changes are usually cosmetic and often tied to listing maintenance, with limited standalone upside and mild negative signaling.
Input: ADEQUATE -
Headline and market context are sufficient because ADS ratio changes rarely create durable catalyst-driven repricing alone.
|
|
2026-09-21 12:02:56
Story: 2026-09-21 08:00:17
|
CUE
ID 6051
|
UNCERTAIN
Up 58% /
Down 42%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
CLINICAL_DATA
ScanScor Filing Bot
|
Reprice: 71% Fade: 82% Thesis Break: 28%
Today:
41.00 -
52.00
|
CUE files 8-K with clinical-trial language
Parse: PARSED
|
Likely 8-K formalizes already announced positive Phase 2 topline data, so attention is warranted but novelty appears limited and fade risk is high.
Input: ADEQUATE -
Recent press release context makes this interpretable, but the filing text appears noisy and may mix boilerplate with current-event language.
|
|
2026-09-21 12:02:27
Story: 2026-09-21 08:00:00
|
JNJ
ID 6050
|
UP
Up 68% /
Down 12%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
CLINICAL_DATA
PRNewswire RSS
|
Reprice: 54% Fade: 42% Thesis Break: 18%
Today:
267.00 -
275.00
|
CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study
Parse: PARSED
|
Positive pivotal Phase 3 mania data expands CAPLYTA’s label opportunity, but JNJ’s huge market cap limits immediate percentage repricing.
Input: ADEQUATE -
Topline efficacy, safety, market cap, and price context are sufficient for an event-reaction judgment.
|
|
2026-09-21 11:35:20
Story: 2026-09-21 07:30:00
|
IFRX
ID 6049
|
UNCERTAIN
Up 8% /
Down 14%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 12% Fade: 78% Thesis Break: 22%
Today:
2.00 -
2.16
|
InflaRx to Host Virtual Capital Markets Day
Parse: PARSED
|
Capital markets day scheduling is routine IR news and lacks new clinical, regulatory, financing, or partnership substance.
Input: ADEQUATE -
News context and trading history are sufficient to classify this as low-urgency routine event news.
|
|
2026-09-21 11:35:14
Story: 2026-09-21 07:30:00
|
MDCX
ID 6048
|
DOWN
Up 22% /
Down 61%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
OTHER
GlobeNewswire RSS
|
Reprice: 58% Fade: 74% Thesis Break: 67%
Today:
0.14 -
0.20
|
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
Parse: PARSED
|
Narrowing focus while ending nBCC development reads as pipeline contraction, not a new catalyst, despite capital-efficiency framing and existing FDA-authorized Gorlin study.
Input: ADEQUATE -
Fresh headline is clear enough: strategic refocus and program termination matter more than prior positive Phase 2 context for immediate reaction.
|
|
2026-09-21 11:33:28
Story: 2026-09-21 07:30:00
|
HELP
ID 6047
|
UNCERTAIN
Up 28% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
CLINICAL_DATA
GlobeNewswire RSS
|
Reprice: 24% Fade: 72% Thesis Break: 8%
Today:
12.10 -
13.35
|
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
Parse: PARSED
|
Conference poster analyses without clearly new topline human efficacy results usually produce limited repricing and any pop is prone to fade.
Input: ADEQUATE -
Need explicit novelty versus prior HLP003 data to justify higher urgency.
|
|
2026-09-21 11:15:16
Story: 2026-09-21 07:00:14
|
TLSA
ID 6046
|
UP
Up 68% /
Down 18%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
OTHER
ScanScor Filing Bot
|
Reprice: 72% Fade: 74% Thesis Break: 29%
Today:
0.87 -
1.08
|
TLSA files foreign issuer report with market-relevant terms
Parse: PARSED
|
Last-patient-last-visit and October topline timing can spark speculative biotech interest, but this is a setup milestone, not efficacy data.
Input: ADEQUATE -
Filing text clearly identifies a current clinical milestone and near-term topline catalyst, sufficient for event-reaction assessment.
|
|
2026-09-21 11:15:12
Story: 2026-09-21 07:00:14
|
SCNI
ID 6045
|
UP
Up 68% /
Down 32%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_UP
COMPLIANCE
ScanScor Filing Bot
|
Reprice: 74% Fade: 88% Thesis Break: 79%
Today:
1.48 -
2.15
|
SCNI files foreign issuer report with market-relevant terms
Parse: PARSED
|
Regaining Nasdaq bid-price compliance removes a near-term delisting overhang, but SCNI remains an extremely fragile microcap prone to pop-and-fade action.
Input: ADEQUATE -
The filing clearly states regained Nasdaq compliance, which is actionable despite noisy tag extraction and weak company quality.
|
|
2026-09-21 11:15:07
Story: 2026-09-21 07:04:32
|
AZN
ID 6044
|
UNCERTAIN
Up 38% /
Down 22%
|
Fish: NO
Chart: NO
MEDIUM
|
ROUTINE_NEWS
REGULATORY
ScanScor Filing Bot
|
Reprice: 31% Fade: 72% Thesis Break: 12%
Today:
164.00 -
169.00
|
AZN files foreign issuer report with market-relevant terms
Parse: PARSED
|
Likely a 6-K packaging already-known positive CHMP and phase 3 details, material but not clearly fresh enough for immediate repricing.
Input: NEED_MORE_FILINGS -
Need the full 6-K and prior press-release timing to confirm whether this filing contains genuinely new regulatory information.
|
|
2026-09-21 11:14:41
Story: 2026-09-21 07:14:05
|
AVTR
ID 6043
|
UNCERTAIN
Up 12% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
ScanScor Filing Bot
|
Reprice: 14% Fade: 78% Thesis Break: 10%
Today:
15.10 -
15.85
|
AVTR files 8-K with clinical-trial language
Parse: PARSED
|
Detected clinical-trial and FDA terms appear boilerplate in an employment-related 8-K, not a concrete catalyst likely to reprice shares.
Input: ADEQUATE -
Enough evidence suggests term-match noise; full 8-K review could confirm, but current excerpts do not show actionable clinical or regulatory news.
|
